STEP-2 Trial: A Plain-English Overview of What It Established

At a glance

| Detail | Value | |---|---| | Trial name | STEP-2 (Semaglutide Treatment Effect in People with Obesity, Trial 2) | | N | 1,210 randomized | | Intervention | Semaglutide 2.4 mg or 1.0 mg subcutaneous once weekly + lifestyle intervention | | Comparator | Placebo subcutaneous once weekly + lifestyle intervention | | Duration | 68 weeks (16-week dose escalation + 52 weeks at maintenance dose) | | Population | Adults with BMI ≥27 kg/m² and type 2 diabetes (HbA1c 7-10%) | | Primary endpoint | Percentage change in body weight from baseline to week 68 | | Key result | -9.6% (sema 2.4 mg) vs -3.4% (placebo); estimated treatment difference -6.2 percentage points (p<0.0001) |

Why This Trial Existed

Before STEP-2, clinicians already knew semaglutide at the 1.0 mg diabetes dose could produce moderate weight loss. What they did not know was whether a higher, obesity-specific dose (2.4 mg) would move the needle far enough in patients with type 2 diabetes, a population where GLP-1-driven weight loss is historically smaller than in people without diabetes.

The STEP-1 trial had demonstrated roughly 15% weight loss in people without diabetes. But patients with type 2 diabetes respond differently. Insulin resistance, concomitant medications (sulfonylureas, insulin), and altered appetite signaling all dampen the weight-loss effect of GLP-1 receptor agonists. STEP-2 was designed to quantify that gap and determine whether the 2.4 mg dose still delivered clinically meaningful results in this harder-to-treat group.

Who Got In, and Who Didn't

The trial enrolled adults aged 18 and older with a BMI of 27 kg/m² or higher, a diagnosis of type 2 diabetes, and an HbA1c between 7% and 10%. Participants had to be on stable treatment with one to three oral antidiabetic medications (metformin, sulfonylureas, SGLT2 inhibitors, or thiazolidinediones) for at least 90 days before screening.

The trial excluded anyone on insulin or other injectable glucose-lowering therapy, those with a history of pancreatitis, and individuals with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, consistent with the boxed warning on GLP-1 receptor agonists. Prior bariatric surgery was also exclusionary.

Baseline characteristics were typical for this population: mean age around 55, mean BMI near 35.7 kg/m², mean HbA1c about 8.1%, and mean diabetes duration of roughly 8 years. Around 72% of participants were on metformin alone or in combination.

The Three-Arm Design

STEP-2 used a three-arm, double-blind, randomized structure. Participants were assigned 1:1:1 to semaglutide 2.4 mg, semaglutide 1.0 mg, or matched placebo, all given as subcutaneous injections once weekly. The 1.0 mg arm was included not for regulatory comparison but as a clinical reference point, since 1.0 mg was the approved diabetes dose of semaglutide (marketed as Ozempic).

All three arms received the same lifestyle intervention: counseling on a 500 kcal/day deficit diet and at least 150 minutes of physical activity per week.

Dose escalation for the 2.4 mg arm followed a 16-week titration schedule, starting at 0.25 mg and increasing monthly: 0.25, 0.5, 1.0, 1.7, then 2.4 mg. The slow ramp was specifically designed to reduce gastrointestinal side effects, the most common reason people discontinue GLP-1 therapy. The 1.0 mg arm escalated over 8 weeks.

What Was Measured

The primary endpoint was percentage change in body weight from baseline to week 68. Two estimands were prespecified: a "treatment policy" estimand (intention-to-treat, regardless of whether participants stayed on drug) and a "trial product" estimand (what happens if you actually take the medication as directed). Both matter. The treatment policy estimand reflects real-world adherence. The trial product estimand reflects pharmacologic efficacy.

Confirmatory secondary endpoints included the proportion achieving ≥5% weight loss, changes in HbA1c, waist circumference, and systolic blood pressure, and quality of life assessed by the IWQOL-Lite-CT questionnaire.

Results: Weight

The headline numbers, using the treatment policy estimand:

| Outcome | Sema 2.4 mg (n=404) | Sema 1.0 mg (n=403) | Placebo (n=403) | |---|---|---|---| | Mean weight change | -9.6% | -7.0% | -3.4% | | ≥5% weight loss | 68.8% | 57.1% | 28.5% | | ≥10% weight loss | 45.6% | 28.7% | 8.2% | | ≥15% weight loss | 25.8% | 13.4% | 3.2% |

The estimated treatment difference between semaglutide 2.4 mg and placebo was -6.2 percentage points (95% CI: -7.3 to -5.2; p<0.0001). In absolute terms, that translated to roughly 10 kg lost with the higher dose versus about 3.7 kg with placebo.

Two observations worth emphasizing. First, the ~10% loss at 2.4 mg in T2D is meaningfully lower than the ~15% seen in STEP-1's non-diabetic population, confirming the longstanding clinical intuition that diabetes blunts pharmacologic weight loss. Second, nearly half the 2.4 mg group reached the ≥10% threshold, a level associated with improvements in obstructive sleep apnea, MASLD, and cardiometabolic risk factors in prior literature.

Results: Glycemic Control

Weight loss was not the only clinically relevant outcome. Mean HbA1c fell by 1.6 percentage points in the 2.4 mg group versus 0.4 points with placebo. About 78.6% of the 2.4 mg group achieved HbA1c <7%, compared to 72.3% in the 1.0 mg group and 36.5% in the placebo group. These improvements are striking because many participants were already on metformin, meaning the glycemic benefit stacked on top of existing therapy.

The FDA label for semaglutide 2.4 mg (Wegovy) ultimately noted weight management as the approved indication, not glycemic control, but STEP-2 data informed clinical thinking about dual benefit.

Safety Profile

Gastrointestinal adverse events dominated, consistent with every GLP-1 receptor agonist trial. In the 2.4 mg group, 63.5% reported GI events versus 34.3% in the placebo arm. The most common were nausea (33.2%), diarrhea (20.4%), and vomiting (12.5%). These events were mostly mild to moderate and tended to occur during the dose-escalation phase, declining as patients reached maintenance.

Discontinuation due to adverse events occurred in 11.6% of the 2.4 mg group, 8.2% of the 1.0 mg group, and 3.5% of the placebo group. GI symptoms accounted for most discontinuations in the active arms.

Gallbladder-related events (cholelithiasis, cholecystitis) were more common with semaglutide, occurring in about 2.6% of the 2.4 mg group versus 1.2% with placebo. Rapid weight loss increases gallstone risk independent of the drug, so this is partly a downstream effect of efficacy. Acute pancreatitis occurred in 2 participants in the 2.4 mg group and 1 in the placebo group, numbers too small to draw conclusions from.

Hypoglycemia rates were low overall. Clinically significant hypoglycemia (blood glucose <54 mg/dL) was uncommon but was more frequent in patients taking concomitant sulfonylureas, an expected finding that the ADA Standards of Care addresses through proactive sulfonylurea dose reduction when adding GLP-1 therapy.

What the Trial Did Not Answer

STEP-2 had real limitations, and the authors acknowledged most of them.

Duration. Sixty-eight weeks is long enough to establish efficacy but not long enough to answer the durability question. The STEP-4 extension trial later showed that weight regain occurs rapidly after semaglutide discontinuation, reinforcing that this is maintenance therapy, not a course of treatment.

Ethnic and racial diversity. Roughly 62% of participants were white, with lower representation of Black, Hispanic, and Asian populations. Diabetes prevalence and GLP-1 pharmacokinetics can differ across ethnic groups.

No insulin-treated patients. The exclusion of patients on injectable glucose-lowering therapy limits generalizability to a large segment of the T2D population. Later real-world studies have begun to fill this gap.

Cardiovascular outcomes. STEP-2 was not powered for MACE endpoints. That question was addressed by the SELECT trial, which demonstrated a 20% reduction in major cardiovascular events with semaglutide 2.4 mg in people with established cardiovascular disease and obesity.

Comparator choice. The trial compared semaglutide to placebo, not to other active weight-loss medications. Head-to-head data against tirzepatide in T2D eventually came from the SURMOUNT-2 trial, which showed numerically greater weight loss with tirzepatide.

What It Means for Practice Today

STEP-2 established three things that still shape prescribing decisions.

First, the 2.4 mg dose produces roughly 2.5 percentage points more weight loss than the 1.0 mg diabetes dose. For a patient already on Ozempic 1.0 mg primarily for weight management, the data support dose escalation. For a patient whose primary goal is glucose control with secondary weight benefit, the 1.0 mg dose may suffice.

Second, clinicians should set realistic expectations. Telling a patient with type 2 diabetes to expect 15% weight loss based on STEP-1 headlines is inaccurate. Nine to ten percent is the evidence-based number. That difference matters when counseling around surgical alternatives.

Third, the glycemic effect means that medication adjustments (particularly sulfonylurea reduction) should be planned proactively at initiation rather than reactively after a hypoglycemic event.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PubMed
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PubMed
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. PubMed
• Wegovy (semaglutide) prescribing information. FDA. Label